Related by context. All words. (Click for frequent words.) 66 Marketing Authorization 63 Marketing Authorisation Application 63 Marketing Authorization Application MAA 62 Marketing Authorization Application 61 Receives Positive Opinion 61 Positive Opinion 61 OMP designation 61 Biologic License Application BLA 61 Fast Track Status 60 Adenuric R 60 Orphan Drug status 60 MAA submission 60 Receives Marketing Authorization 59 Decentralized Procedure 59 Marketing Authorization Applications 59 Accelerated Assessment 58 Centralized Procedure 58 European Medicines Evaluation 58 Angiox ® 58 Receives Complete Response 58 GTC recombinant form 58 Orphan Drug Status 58 Marketing Authorisation 58 FDA Complete Response 57 Expedited Review 57 FIRAZYR 57 Phase III Clinical Trial 57 Orphan Status 57 orphan designation 57 FDA Approvable Letter 57 Pre IND 57 ARIXTRA R 57 Marketing Authorisation Application MAA 57 BLA filing 57 Accelerated Approval 57 Orphan Designation 57 Approvable 57 Application MAA 57 Pirfenidone 57 FDA Accepts 57 Esbriet ® 57 MEPACT 56 ACCLAIM II 56 Mutual Recognition Procedure 56 Biologic License Application 56 Market Authorization Application 56 Trobalt 56 Rhucin R 56 CONBRIZA 56 European Medicines Agency 56 CHMP recommendation 56 Receives Orphan Drug Designation 56 Ranolazine 56 Phase III Trial 56 Resubmission 56 GTC recombinant human 56 Orphan Drug designation 55 Certican 55 Lambert Eaton Myasthenic 55 StaphVAX R 55 orphan medicinal product 55 Clinical Guideline 55 EGTT 55 Zebinix R 55 OMAPRO ™ 55 PIX# [002] 55 Velaglucerase Alfa 55 CHMP opinion 55 Cintredekin besudotox 55 Pivotal Phase III 55 Orphan Medicinal Product 55 eprodisate KIACTA TM 55 PROVENGE ® 55 JAK2 Inhibitor 55 Basilea Toctino R 55 Evoltra TM 55 ATryn R 55 Phase IIb Trial 55 Medicinal Products EMEA 55 REBETOL combination therapy 55 SYCREST 55 Seasonal Influenza Vaccine 55 Phase 2a Trial 55 KRYSTEXXA TM 54 Plenaxis R 54 Initiates Phase III 54 refractory chronic lymphocytic 54 Nivestim 54 supplemental Biologics License Application 54 Granted Orphan Drug 54 Plicera 54 YONDELIS R 54 RIGScan CR 54 SPERA 54 SUTENT ® 54 submitted Marketing Authorisation 54 Premarket Approval PMA 54 Receives Milestone Payment 54 Complete Response 54 Yondelis ® 54 histamine dihydrochloride 54 Pivotal Trial 54 Icatibant 54 Phase IIb Clinical Trial 54 Expanded Indication 54 Japanese Encephalitis Vaccine 54 CIP TRAMADOL ER 54 Complete Response Letter CRL 54 Initiates Clinical 54 Thalidomide Pharmion 54 Human Medicinal Products 54 Peginterferon alfa 2b 54 Slovenian Presidency 54 Final Appraisal Determination 54 CHMP 53 Fast Track Designation 53 SCHWARZ PHARMA 53 ACOMPLIA R 53 JOULFERON 53 Receives Orphan Drug 53 FOLOTYN ® 53 vinorelbine emulsion 53 XIAFLEX TM 53 Fresenius Biotech 53 Androxal ® 53 Xyrem ® 53 SEBIVO 53 Phase 2a Study 53 Telzir 53 interferon gamma 1b 53 Notified Bodies 53 Fondaparinux 53 Glatiramer Acetate 53 Esbriet pirfenidone 53 TEMODAL 53 Clinical Trial 53 Complete Response letter 53 Rhucin ® 53 Swissmedic 53 Metastatic Colorectal Cancer 53 Somatuline R Autogel R 53 Files Investigational 53 Tostrex 53 Phase 1b Clinical Trial 53 STO SOBI 53 Firdapse ™ amifampridine phosphate 53 Retacrit 53 Patient Enrollment 53 Randomized Phase II 53 Nabi HB Intravenous 53 Issues Complete Response 53 rolling Biologics License 53 Japanese Encephalitis vaccine 53 Raptiva R 53 Confirmatory Phase 53 Investigational Device Exemption 53 Cimzia ® certolizumab pegol 53 IND Investigational New 53 Amigal 53 NOXAFIL 53 Complicated Skin 53 VIVITROL ® 53 Contrave NDA 53 Meets Primary Endpoint 53 Civacir 53 Rasilamlo 53 Febuxostat 53 Ambrisentan 53 Dyloject TM 53 Kuvan R 53 #D#C# 53 Junovan 53 FDA Anti Infective 52 Clinical Trial Results 52 Orphan Drug Designation 52 Soliris TM eculizumab 52 Desvenlafaxine 52 SNT MC# 52 Dalbavancin 52 Firdapse TM amifampridine phosphate 52 Files IND 52 Approvable Letter 52 Phase III multicenter 52 Dupuytren Contracture 52 Submits NDA 52 balsalazide tablet 52 Product Characteristics 52 XIAPEX ® 52 Glybera R 52 Biologics License Application 52 Supplemental Biologics License Application 52 Glufosfamide 52 KRYSTEXXA TM pegloticase 52 Cethromycin 52 GATTEX TM 52 Hedgehog Pathway Inhibitor 52 orBec 52 liver resection surgeries 52 Marketing Authorizations 52 CHMP Opinion 52 commercialize oritavancin 52 Cladribine Tablets 52 Teysuno 52 JZP 52 CAMPATH R 52 Rasilez HCT 52 Zenvia Phase III 52 ® decitabine 52 POSIDUR TM 52 IV acetaminophen 52 Phase 1a clinical 52 Pixuvri 52 Investigational Treatment 52 PDUFA Date 52 Completes Patient Enrollment 52 Receives Approvable Letter 52 Orphan Drug designations 52 Receives CE Marking 52 Toctino R 52 Complete Response Letter 52 Submits Response 52 ATPace TM 52 FDA Accelerated Approval 52 Sanvar R 52 PHX# 52 orphan medicinal 52 IND submission 52 Drug Approvals 52 Tesamorelin 52 Bioral Amphotericin B 52 Trovax 52 Recommends Approval 52 Romiplostim 52 Æterna Zentaris 52 Topline Results 52 LibiGel ® 52 Diamyd Medical Diamyd 52 Product Designation 52 Initiate Phase III 52 Cetrorelix 51 CERVARIX R 51 Tracleer r 51 mifamurtide 51 Presents Positive 51 Clinical Trial Evaluating 51 Biological License Application 51 Zenvia ™ 51 ANTEGREN 51 Arzerra ofatumumab 51 PNP inhibitor 51 Medicure Announces 51 hypereosinophilic syndrome 51 Orphan Medicinal Products 51 alvimopan 51 LUMINATE 51 NDA Submission 51 Cellegesic 51 GTC NASDAQ GTCB 51 cytokine immunomodulator 51 PIX# trial 51 Intravenous Formulation 51 Sanofi aventis EURONEXT SAN 51 Toctino ® 51 PrevOnco 51 DIFICID ™ 51 Lenalidomide 51 Raptiva ® 51 XIAFLEX ™ 51 sNDA submission 51 Phase III Clinical Trials 51 Initiate Phase 51 Pivotal Phase 51 IRESSA 51 IMA# 51 PMA submission 51 QNEXA ® 51 Orathecin 51 received CE Conformite 51 Unanimously Recommends 51 Centralised Procedure 51 Cimzia certolizumab pegol 51 Cutaneous T 51 Emezine 51 Conditional Approval 51 REVLIMID R 51 cUTI 51 Satraplatin 51 Uvidem 51 KRN# 51 Long Term Efficacy 51 SmPC 51 Elagolix 51 Demonstrates Sustained 51 Proprietary Medicinal Products CPMP 51 EGRIFTA TM 51 AVI BioPharma Announces 51 PREOS R 51 ECVAM 51 submit Biologics License 51 Submits Supplemental 51 Prostate Cancer Vaccine 51 Premarket Approval 51 Alogliptin 51 Noxafil 51 Clinical Study 51 Oral Calcitonin 51 rasagiline tablets 51 Drug Submission 51 Immunotherapeutic 51 Schizophrenia Drug 51 TORISEL 51 Patent Covering 51 Alvesco R 51 SPRYCEL ® 51 submitted Marketing Authorization 51 Aloxi Injection 51 Ceplene 51 Pandemic Influenza Vaccines 51 AZILECT ® 51 Phase Ib study 51 severe hypercholesterolemia 51 cSSTI 51 Successfully Completes Phase 51 Firdapse 51 Orthopedic Advisory Panel 51 BRIM3 51 Initiates Phase II 51 Torisel 51 Evoltra R 51 Neupro ® 51 Psoriasis Drug 51 Hexvix 51 Syndrome LEMS 51 Taro Receives 51 Colorectal Cancer Patients 51 registrational 51 novel orally inhaled 51 CRMD# 51 Prestara TM 51 Decentralized Procedure DCP 51 Removab 51 ELIQUIS 51 Troxatyl TM 51 Omapro 51 Ceplene ® histamine dihydrochloride 51 tocilizumab 51 PROMACTA 51 Oracea ® 51 BrachySil TM 51 Receives Positive 51 Preotact 51 Zevtera TM 51 Ofatumumab 51 Surfaxin lucinactant 50 Recombinant Human 50 BLA submission 50 MYLOTARG 50 acyclovir Lauriad R 50 Phase 2b Clinical Trial 50 BENLYSTA ® 50 Ceftobiprole 50 Advanced Melanoma 50 human antithrombin 50 BESST 50 Receives Fast Track 50 Prospective Randomized 50 acyclovir Lauriad ® 50 Data Suggest 50 Special Protocol Assessment 50 Gaucher Disease 50 Silenor NDA 50 ZEGERID Chewable Tablets 50 Focetria 50 Grants Orphan Drug 50 Drug Eluting Stent System 50 LibiGel NDA 50 Glybera 50 registrational trial 50 TWYNSTA ® 50 Onrigin 50 Brentuximab Vedotin SGN 50 Virulizin R 50 tramiprosate ALZHEMED TM 50 OPAXIO 50 Investigational Agent 50 generation purine nucleoside 50 Firazyr 50 Serdolect ® 50 Loramyc R 50 Randomized Phase 50 Antiviral Drugs Advisory 50 Zalbin 50 Acetavance TM 50 IND Filing 50 Rheumatoid Arthritis Drug 50 Ruconest 50 Mepact 50 Cloretazine ® 50 Gout Drug 50 Evoltra ® 50 STELARA TM 50 MabCampath 50 REG1 Anticoagulation System 50 NASDAQ Delisting Notice 50 AZILECT R 50 novel emulsion formulation 50 Biologics Licensing 50 Methylnaltrexone 50 Vascular Disrupting Agent 50 Intermezzo ® NDA 50 Surfaxin LS 50 Evoltra 50 hoFH 50 Application BLA 50 SNT-MC#/idebenone 50 Clevudine 50 NEBIDO 50 Schizophrenia Treatment 50 Subpart E 50 Paragraph IV Notice 50 Biologics License Application BLA 50 Nicotine Vaccine 50 Eribulin 50 Million Milestone Payment 50 BioDelivery Sciences 50 Principle AIP 50 Panflu TM Sinovac 50 Mylan Receives Approval 50 Entocort 50 NerPharMa 50 Angiox 50 Arzerra TM 50 sNDA 50 guanfacine extended release 50 Aryplase 50 Adjuvant Treatment 50 Mimpara 50 Ocrelizumab 50 Rotavirus Vaccines 50 Veronate 50 Tracleer R 50 sBLA 50 Initiates Enrollment 50 SUCCEED trial 50 Notified Body 50 ECOFIN Council 50 Linjeta TM 50 Marketing Authorisations 50 Dacogen injection 50 Lodotra 50 Pivotal Study 50 Anturol TM 50 Barr ANDA 50 THELIN 50 Photocure 50 BfArM 50 Sebivo 50 Combination REOLYSIN R 50 ALVESCO R 50 human C1 inhibitor 50 XIAPEX 50 Neupro R 50 Prepandrix 50 Regulatory Approvals 50 Ceflatonin 50 Sycrest 50 APTIVUS ritonavir 49 Epidemiological Studies Unit 49 Pandemic Influenza Vaccine 49 Randomized Controlled Trials 49 Onrigin TM 49 Santhera 49 proprietary transdermal patch 49 MEK Inhibitor 49 FDA Oncologic Drugs 49 LEVADEX TM 49 myelodysplastic myeloproliferative diseases 49 Clinical Trial Application 49 taliglucerase alfa 49 Orazol 49 Premarket Approval Application 49 Severe VOD 49 Alitretinoin 49 Entereg R 49 Erythropoiesis Stimulating Agents ESAs 49 Kit CD# positive 49 Confirmatory 49 Multiple Myeloma Patients 49 Medicinal Products 49 ANDA Filing 49 CryoSeal FS System 49 Adenuric ® 49 Safinamide 49 budesonide MMX Phase III 49 methylnaltrexone bromide 49 PRECISE Trial 49 Silenor ® doxepin 49 Begins Dosing 49 CDM EB 49 Increlex R 49 codecision procedure 49 APEX AMI trial 49 sorafenib tablets 49 Clinical Trial Data 49 MEND CABG II 49 First Patient Enrolled 49 BLAs 49 submitted supplemental Biologics 49 Phase 2a clinical trials 49 Interoperability Standards 49 Aflunov 49 intravenous iclaprim 49 BioNumerik 49 Stockholder Approval 49 DORIBAX 49 synthetic lipoglycopeptide antibiotic 49 PANVAC VF 49 Restanza 49 Metastatic Melanoma 49 Not Approvable 49 Advagraf 49 AVASTIN 49 Oncologic Drugs Advisory 49 evaluating satraplatin 49 Voraxaze 49 ADVEXIN p# therapy 49 EGRIFTA ™ 49 www.soliris.net 49 Expert Advisory Panel 49 ADVANCE PD 49 Announces Tentative Approval 49 Second Pivotal Phase 49 registrational studies 49 Patent Broadly Covering 49 Submits Investigational 49 Eniluracil 49 Fast Track designation 49 Ahtisaari Plan 49 CELVAPAN H#N# 49 Xcytrin R 49 Informal consultations 49 methylnaltrexone 49 TYGACIL 49 Cimzia ® 49 KYNAPID 49 Taxotere ® 49 Entereg TM 49 Completes Enrollment 49 vapreotide acetate 49 Antithrombin 49 NexMed Receives 49 Telavancin 49 BLP# Liposome Vaccine 49 PRIALT 49 ACTEMRA TM 49 Mutual Recognition 49 Traficet EN 49 TYZEKA 49 Vernalis plc 49 MAAs 49 ORENCIA ® 49 Lamfalussy process 49 Zevtera ™ 49 WHO prequalification 49 treat opioid induced 49 BCR ABL inhibitor 49 Submits Application 49 PROVENGE sipuleucel T 49 L MTP PE 49 Formal Dispute Resolution 49 Rhucin 49 GRAS notification 49 ATryn ® 49 lucinactant 49 tiapamil 49 MERLIN TIMI 49 rilonacept 49 RoACTEMRA 49 NASDAQ CXSP announced 49 SUBOXONE 49 Amrubicin 49 liposomal formulation 49 Pre Filled Syringes 49 eCTD format 49 PDX pralatrexate 49 forodesine 49 PROVIGIL 49 CAELYX 49 Jevtana 49 FDA approvable letter 49 ATryn ® GTC recombinant 49 Aviptadil 49 Loramyc ® 49 Vasovist 49 IgG1 monoclonal antibody 49 granted Ortec 49 Study Evaluating 49 Vimpat R 49 Prodarsan R 49 Egrifta 49 Personalized Immunotherapy 49 BiDil XR 49 BiTE R 49 FIRMAGON R 49 Begin Clinical Trials 49 Somatuline Depot 49 Pivotal Clinical Trial 49 NYSE Amex Listing 49 Testosterone MDTS ® 49 PMA Supplement 49 NESINA 49 Rhucin ® recombinant 48 Fast Track designations 48 SURFAXIN 48 Onalta ™ 48 ezogabine 48 Unsolicited Proposal From 48 GMP Certificate 48 Fibrillex TM 48 Phase III Pivotal 48 Vimpat ® lacosamide 48 Genasense ® 48 Diamyd r 48 Clinical Trial Enrollment 48 SWX BSLN 48 FACTIVE tablets 48 Zerenex 48 Testosterone Gel 48 Pulmonary Allergy Drugs 48 Clofarabine 48 Product Monograph 48 CE Marking 48 BRILINTA 48 Investigational Compound 48 RELISTOR ® 48 Hexvix ® 48 Anti Infective Drugs 48 k Premarket Notification 48 Investigational Drugs 48 Brilique 48 Orapred ODT 48 Cinryze TM 48 PrandiMet 48 CLIA waiver 48 Initiate Phase II 48 Panzem R 48 SEROQUEL XR 48 Receives Approval From 48 Prestara 48 investigational antiplatelet agent 48 Rheumatoid Arthritis Patients 48 TM pralatrexate injection 48 Risperidone Oral Solution 48 trastuzumab DM1 T DM1 48 leading oral taxane 48 MOZOBIL 48 velaglucerase alfa 48 Approvable letter 48 REVLIMID lenalidomide 48 Regulatory Clearance 48 Submits Biologics License Application 48 ENLIGHT 48 ANVISA 48 submitted Biologics License 48 Spectrum Pharmaceuticals Announces 48 sapropterin dihydrochloride 48 Golimumab 48 Therapy Evaluation 48 pralatrexate 48 Tumor Response 48 refractory cutaneous T 48 Bonefos 48 PDUFA Prescription Drug 48 PROMACTA CARES 48 Nexavar sorafenib 48 Ceplene histamine dihydrochloride 48 FDA Dermatologic 48 Cladribine 48 randomized controlled Phase 48 TORISEL TM 48 HuMax CD4 48 Genasense oblimersen sodium Injection 48 Diamyd ® 48 CancerVax Corporation 48 Nexavar ® 48 ONGLYZA TM 48 Diabetic Macular Edema 48 Alemtuzumab 48 Analytical Method 48 nasal calcitonin product 48 AOP Orphan 48 Allovectin 7 r 48 Increlex TM 48 NASDAQ AVNR 48 MelaFind R 48 Orphan Drug 48 Fodosine 48 relapsing remitting MS RRMS 48 MDUFMA 48 Intravenous Hepatitis B 48 pertussis Tdap vaccine 48 MHLW 48 BYETTA ® 48 Investigational 48 sNDAs 48 HeartWare System 48 EDQM 48 highly purified pasteurized 48 irinotecan containing 48 silodosin 48 Torisel temsirolimus 48 Jerini AG 48 Sprycel dasatinib 48 Generic Version 48 trabectedin 48 Ganite ® 48 Nasdaq ONXX today 48 oral ridaforolimus 48 PhotoCure 48 Phase III HEAT 48 Tasigna nilotinib 48 LUVENIQ 48 metastatic castrate resistant 48 LHRH antagonist 48 Orphan designation 48 Inhaled Insulin 48 EGFR expressing mCRC 48 rotigotine transdermal patch 48 Patients Suffering 48 HFA MDI 48 refractory Hodgkin lymphoma 48 adjuvant GIST 48 Renal Tumors 48 Omigard TM 48 Mirapexin 48 ospemifene 48 Loramyc ™ 48 Ceflatonin R 48 ISTODAX 48 Phase IIIb clinical 48 prucalopride 48 FDA Advisory Panel 48 APPRAISE 48 Zavesca r 48 BENLYSTA 48 Artificial Cornea 48 Qutenza TM 48 Tectin TM 48 REMOXY NDA 48 EvaMist TM 48 personalized cellular immunotherapy 48 ThermoDox ® 48 Rasagiline 48 Prostate AdenoCarcinoma Treatment 48 Simulect 48 IMPELLA R 48 Jerini 48 COMFORT II 48 NASDAQ INGN 48 indiplon capsules 48 paliperidone palmitate 48 Liprotamase 48 transfusional iron overload 48 APF# NDA 48 Glycopyrrolate 48 lorcaserin Phase 48 FDA Orphan Drug 48 ZEFTERA TM 48 BEMA Granisetron 48 Proprietary Medicinal Products 48 pralatrexate injection folate analogue 48 NASDAQ FLML 48 Nanoscale Materials Stewardship 48 TYKERB 48 MuGard TM 47 mesylate tablets approved 47 Unsolicited Tender Offer 47 Stakeholder Workshop 47 Preotact R 47 Impax ANDA 47 FDA Clearance 47 ATL# [001] 47 telavancin NDA 47 Afinitor ® 47 TRANSDUR ™ 47 Aztreonam Lysine 47 Shareholder Approval 47 Modrenal R 47 Abstral 47 Entereg alvimopan 47 ceftobiprole 47 TAXUS Element Stent System 47 vinflunine 47 Stockholder Vote 47 Exploitation Concession 47 Ebola Vaccine 47 OTCQX QRXPY 47 autologous cellular immunotherapy 47 Obtains Regulatory 47 confirmatory pivotal 47 Pharmacopeial Convention 47 Tarceva TM 47 custirsen 47 Voluntary Withdrawal 47 dihydrochloride Tablets 47 NASDAQ CGEN announced 47 Wyeth Torisel 47 Outlines Priorities 47 Zenpep 47 Performers List 47 ABILIFY R 47 Genasense R 47 Priority Review 47 Luveris 47 Lupus Drug 47 Phase #b/#a clinical 47 Use Authorization EUA 47 Oracea TM 47 Belimumab 47 initiate Phase IIb 47 Junovan TM 47 Triage Stroke Panel 47 Keryx Biopharma 47 confirmatory Phase III 47 ADVEXIN 47 humanized anti 47 Receives Conditional 47 Drug Fails 47 GARDASIL ® 47 rALLy clinical trial 47 CNTO 47 granted orphan medicinal 47 QNEXA 47 casopitant 47 ELACYT 47 phase IIb 47 Laryngeal Cancer 47 VIVUS Announces 47 phase Ib 47 Onalta 47 HCV SPRINT 47 Iluvien ® 47 Clinical Trial Investigating REOLYSIN 47 Nasdaq DVAX 47 Flutiform ™ 47 Allovectin 7 ® 47 Decitabine 47 EGRIFTA 47 Stereotaxis Announces 47 Nycomed GmbH 47 balsalazide disodium 47 Stefan Lehne 47 Vitrasert R 47 WILEX 47 investigational humanized monoclonal antibody 47 peginesatide 47 MAGE A3 ASCI 47 Fludara ® 47 Combating Climate Change 47 Sanofi Acomplia 47 GRAS Status 47 GATTEX ® 47 NOPR 47 Velcade bortezomib 47 Advanced Renal Cell 47 Phase IIB 47 TELINTRA R 47 FDA Approvals 47 GP Pharm 47 ENRICH trial 47 Luveniq 47 systemic immunosuppressive drugs 47 BRIM2 47 investigational immunotherapy 47 pivotal bioequivalence 47 FACTIVE R gemifloxacin 47 Nasdaq EPCT 47 NASDAQ NYMX 47 Forsteo 47 CCHIT Certification 47 Rectogesic 47 Sodium Injection 47 NEO3 47 RhuDex 47 molecular imaging radiopharmaceutical 47 GHTF 47 eprodisate Fibrillex TM 47 evaluating carfilzomib 47 Milestone Payments 47 lorcaserin NDA 47 Adalimumab 47 Keppra ® 47 Tamibarotene 47 Carbidopa Levodopa 47 donepezil rivastigmine 47 M Enoxaparin 47 SPL# Gel vaginal microbicide 47 TLK# 47 Phase IIb trials 47 EMPOWER ™ 47 TRX1 47 Mycamine 47 SABER ™ 47 RANK Ligand inhibitor 47 OvaRex ® MAb 47 Phase Ib II 47 pemetrexed Alimta 47 See CLINICAL PHARMACOLOGY 47 Urocidin TM 47 Vitaros 47 Receives Tentative FDA 47 Marketing Approval PMA 47 Darunavir 47 Provisional Measures 47 Investigational Device Exemption IDE 47 Act PDUFA date 47 DATES Comments 47 NASDAQ BDSI 47 Faropenem 47 FDA Approval 47 Troop Realignment 47 SPARLON 47 Aflibercept 47 DASISION 47 pain palliation 47 ixabepilone 47 Calcium Acetate 47 Gene Therapy Advisory 47 REMICADE ® 47 Augment Injectable 47 pulmonology portfolio 47 Ixempra 47 OLpur TM H2H 47 vandetanib 47 Epilepsy Drug 47 Panzem R NCD 47 VALOR trial 47 Phase #b/#a 47 midstage clinical 47 rALLy trial 47 NASDAQ SHPGY 47 Clolar 47 Alzhemed TM 47 EOquin 47 Humenza 47 Strasbourg Kehl Summit 47 PREOS 47 postapproval 47 SIMPONI TM 47 PrevOnco ™ 47 Hematide ™ 47 supplemental biologics 47 License Application 47 Biophan patent 47 Azilect ® 47 Genetically Engineered Animals 47 remission induction 47 VPRIV 47 Bezielle 47 Aphthasol R 47 Anidulafungin 47 phase IIb clinical 47 EGFR expressing metastatic colorectal 47 R lenalidomide 47 Ethical Guidelines 47 Nexavar tablets 47 Crofelemer budesonide foam 47 Proposed Rule Changes 47 EPAR 47 prGCD 47 HEPLISAV ™ 47 Loramyc 47 TRISENOX 47 placebo controlled Phase III 47 Phenoptin 47 Bicifadine 47 N acetylgalactosamine 6 47 FRDA 47 IL# PE#QQR 47 Renal Cell Carcinoma RCC 47 Coronary Revascularization 47 Resubmit 47 MyVax R 47 UPLYSO 47 Reclast Aclasta 46 TMC# [002] 46 TOCOSOL Paclitaxel 46 Gentamicin Surgical Implant 46 LUX Lung 46 sublingual tablets 46 y Ambiente SERNA Honduras 46 Perifosine 46 multicenter phase 46 Joulferon 46 Pixantrone 46 Movectro 46 Consultation Document 46 Anti Clotting Drug 46 Xanafide